ArticleVirusdisease2025
Development of a multi-epitope vaccine candidate targeting conserved regions of human metapneumovirus.
Article in Virusdisease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (HMPV) is a globally distributed respiratory virus that can infect individuals of all ages. Infections can lead to severe respiratory illnesses, particularly in young children, the elderly, and immunocompromised individuals. Due to the genetic variability of HMPV and the absence of a vaccine, there is an urgent need for effective vaccine development. This study employed in silico immunoinformatics approaches to design a multi-epitope vaccine targeting the conserved regions fusion glycoprotein (F) of HMPV. A total of 18 highly conserved, antigenic, non-toxic, and non-allergenic epitopes were identified, including 5 B-cell epitopes, 8 cytotoxic T lymphocyte (CTL) epitopes, and 5 helper T lymphocyte (HTL) epitopes. These epitopes were linked using appropriate linkers, and an adjuvant was incorporated to enhance immunogenicity. Computational analyses predicted the vaccine construct to be antigenic, non-allergenic, and non-toxic. Molecular docking studies with Toll-like receptor 4 (TLR4) demonstrated a strong binding affinity, with a binding energy of - 112.7 ± 9.7 kcal/mol and a Z-score of - 2.5. Molecular dynamics simulations further confirmed the stability of the vaccine-TLR4 complex. Immune simulation analysis predicted robust immune responses, including elevated levels of IgM, IgG1, IgG2, and combined IgG + IgM. Finally, in silico codon optimization and cloning analysis indicated that the vaccine construct could be efficiently expressed in Supplementary Information: The online version contains supplementary material available at 10.1007/s13337-025-00932-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.